GoHealth (GOCO) Q4 2025 earnings summary

Executive summary

• Net revenues declined 54.7% year-over-year to $361.8 million, driven by a strategic pullback in Medicare Advantage activities and a shift toward cash preservation and retention over new sales.

• The company recorded a net loss of $497.8 million, including $260 million in impairment charges related to trade names, intangible assets, and other long-lived assets due to reduced forecasted cash flows.

• Operational focus shifted to cost reduction, efficiency, and the launch of GoHealth Protect, a new product line targeting life insurance and financial protection needs.

• Strategic capital actions included a new $115 million superpriority term loan, amendments to existing credit agreements, and the creation of a Transformation Committee to explore strategic alternatives.

Financial highlights

• Net revenues: $361.8 million in 2025, down from $798.9 million in 2024.

• Net loss: $497.8 million in 2025, compared to a net loss of $7.3 million in 2024.

• Adjusted EBITDA: $(35.1) million, down from $120.3 million in 2024.

• Operating expenses: $774.7 million, including $259.9 million in impairment charges.

• Cash and cash equivalents: $32.9 million as of December 31, 2025.

• Debt: $688.5 million outstanding under term loan facilities at year-end.

Outlook and guidance

• Management expects current liquidity sources to be sufficient for the next twelve months but acknowledges risk of covenant non-compliance and ongoing discussions with lenders regarding further capital structure modifications.

• The company will continue to prioritize cash preservation, operational efficiency, and strategic flexibility, with a focus on core capabilities and new product initiatives.